July 29, 2009 (FinancialWire) — Watson Pharmaceuticals, Inc. (NYSE: WPI) said it has inked a license agreement with GeneraMedix, Inc., for the exclusive U.S. marketing rights to a generic version of Ferrlecit, a used to treat iron deficiency anemiain hemodialysis patients.

Ferrlecit, which is generically known as sodium ferric gluconate complex, is indicated for the treatment of iron deficiency anemia hemodialysis patients receiving supplemental epoetin therapy.

GeneraMedix has an abbreviated new drug application on file with the FDA for a sodium ferric gluconate complex in sucrose product that is packaged in a vial. The application is under expedited review with the FDA.

Under the terms of the agreement, GeneraMedix will supply the product to Watson, which will market, sell and distribute the product in the U.S. Terms of the license agreement have not been disclosed.

Watson currently markets the brand product, Ferrlecit, under a supply and distribution agreement with Sanofi-Aventis. The Ferrlecit product rights return to Sanofi-Aventis on December 31.

Morristown, New Jersey-based Watson Pharmaceuticals is engaged in the development and distribution of pharmaceuticals and has a portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on urology, gynecology and nephrology.

Liberty Corner, New Jersey-based GeneraMedix is a privately held pharmaceutical company specializing in injectable products for the U.S. hospital and specialty markets.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.